Recent Posts
Archives
- July 2016
- May 2016
- February 2016
- September 2015
- July 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
advocacy
assistant secretary koh
Assistant Secretary of Health
Call to Action
canadian consensus
case definitions
CCC
CDC
cfs
CFSAC
chronic fatigue syndrome
comment
committee members
consensus definition
cooling vests
definition
Designated Federal Officer
development initiative
DHHS
disability
disabling
early onset ME
early onset ME/CFS
FDA
fda gov
food and drug administration
government
GWI
health
HHS
howard koh
IACFS/ME
IACFS/ME Primer
IOM
IOM. DHHS/IOM proposed contract
IOM clinical diagnostic criteria
janet woodcock
Jennie Spotila
Mary Dimmock
ME
ME/CFS
medicine
mentors
myalgic encephalomyelitis
national institutes of health nih
NIH
OccupyCFS
OI
orthostatic intolerance
P2P
participate
participation
Phoenix Rising
politics
POTS
public comment
registration
release forms
research
science
Sebelius
Speak Up About ME
spring 2012
SSDI/SSI
Stakeholders Meeting
support
supporters
survey
treatment
upcoming events
video
Voices From The Shadows
volunteers
Washington
young people
Summary of April 26, 2013 FDA meeting (day 2)
Published February 27, 2014 Uncategorized Leave a CommentTags: advocacy, cfs, chronic fatigue syndrome, Drug Development, FDA, food and drug administration, ME, myalgic encephalomyelitis, participate, public comment
Recently FDA released a summary (http://www.fda.gov/Drugs/NewsEvents/ucm386705.htm) of the April 26, 2013 FDA Workshop on Drug Development for Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME). You may recall that this was the second day of a 1.5 day meeting and on this day, there were discussions about identifying quantitative outcome measures and determining which treatments produce improvements.
Remember that FDA is currently producing a guidance document for CFS and ME drugs that will provide advice for pharmaceutical companies and industry to expedite research for treatments. Our input will be needed on this. Note – typically when a draft guidance is released there is a 60 day comment period.
Additional information about the meeting and links to transcripts etc. can be found here: http://www.fda.gov/Drugs/NewsEvents/ucm369563.htm
Share this: